KRAS and colorectal carcinoma: KRAS mutations in colorectal cancer are commonly associated with a MSS phenotype and poor response to single−agent immune checkpoint inhibitors; notably, in the KEYNOTE−177 trial, MSI−H CRC patients harboring KRAS or NRAS mutations did not benefit from ICI monotherapy (43).